Search results
Results from the WOW.Com Content Network
The genetic cause of Bare lymphocyte syndrome type II is due to mutations in any of the following genes: [5]. CIITA is responsible for giving instructions to create a protein that controls transcription of genes (MHC class II), and is located at 16p13.13 (cytogenetic location), [6]
Clinically, this is similar to severe combined immunodeficiency (SCID), in which lymphocyte precursor cells are improperly formed. Absolute T-cell count is also reduced, due to impaired development with the absence of MHC II. [3] BLS I is characterised by a lack of MHC I molecules.
The T helper cells (T h cells), also known as CD4 + cells or CD4-positive cells, are a type of T cell that play an important role in the adaptive immune system. They aid the activity of other immune cells by releasing cytokines .
Markers of T cell activation include CD69, CD71 and CD25 (also a marker for Treg cells), and HLA-DR (a marker of human T cell activation). CTLA-4 expression is also up-regulated on activated T cells, which in turn outcompetes CD28 for binding to the B7 proteins. This is a checkpoint mechanism to prevent over activation of the T cell.
CD4 is found on the surface of immune cells such as helper T cells, monocytes, macrophages, and dendritic cells. It was discovered in the late 1970s and was originally known as leu-3 and T4 (after the OKT4 monoclonal antibody that reacted with it) before being named CD4 in 1984. [ 5 ]
Although all CD4+ T cells gut are severely depleted by HIV, the loss of intestinal T h 17 cells in particular has been linked to symptoms of chronic, pathogenic HIV and SIV infection. Microbial translocation is a major factor that contributes to chronic inflammation and immune activation in the context of HIV. [ 31 ]
Artificial antigen presenting cells (aAPCs) are engineered platforms for T-cell activation. aAPCs are used as a new technology and approach to cancer immunotherapy. Immunotherapy aims to utilize the body's own defense mechanism—the immune system —to recognize mutated cancer cells and to kill them the way the immune system would recognize ...
CD4 + T-lymphocytes differentiate into Th1 helper cells in the presence of IL-12 (which is usually secreted by mature dendritic cells). Th1 cells produce proinflammatory cytokine IFN-γ and destroy the allograft tissue. If there is IL-4, CD4 + T-lymphocytes become Th2 cells secreting IL-4 and IL-5. [3] Then allograft tolerance is mostly ...